01 June 2021 | News
Lilly is working with the Indian government to provide donations of bamlanivimab and etesevimab
Image Credit: shutterstock.com
Eli Lilly and Company, India has received restricted emergency use approval (EUA) of its antibody drugs, bamlanivimab 700 mg and etesevimab 1400 mg, in India for the treatment of patients with mild to moderate coronavirus disease 2019 (COVID-19).
Bamlanivimab and etesevimab together are indicated for restricted use in an emergency, IV route for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) for injection administration in hospital settings in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with RT-PCR positive results of direct SARS-COV2 viral testing and who are at high risk for progressing to severe COVID-19 and/or hospitalization and do not require oxygen.
Lilly is engaging in active dialogue with the Indian government and regulatory authorities to donate bamlanivimab and etesevimab to speed up access and provide treatment options for patients with COVID-19.
Bamlanivimab and etesevimab together have been authorised under Emergency Use Authorization in the US and select EU countries, for the treatment of mild to moderate COVID-19.
Speaking about its benefits for patients with COVID-19, Luca Visini, Managing Director, India Subcontinent, Lilly India, said, “We are pleased that we have another innovative treatment option to offer India’s healthcare providers who continue to be at the forefront of the battle against COVID-19. Lilly is committed to contributing to the alleviation of the COVID-19 pandemic in India and around the world. We will continue to assess and evaluate how our existing portfolio and ongoing research can benefit patients with COVID-19.”